ACM
TEVA icon

Alethea Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Alethea Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-30,669
Closed -$1.54M – 76
2016
Q2 		$1.54M Buy
+30,669
New +$1.63M 2.11% 20
2016
Q1 		– Sell
-19,123
Closed -$1.25M – 85
2015
Q4 		$1.25M Buy
+19,123
New +$1.18M 1.45% 25

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Alethea Capital Management's TEVA Position: Q3 2016 in Review

Alethea Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 30,669 shares — an estimated $1.54M sold.

Alethea Capital Management first reported a position in TEVA in Q4 2015 and held it in 2 quarters. The position peaked at $1.54M in Q2 2016. 795 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

  • Alethea Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Alethea Capital Management sold 30,669 Teva Pharmaceuticals shares in Q3 2016, an estimated $1.54M.
  • Alethea Capital Management first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Alethea Capital Management's Teva Pharmaceuticals position peaked at $1.54M in Q2 2016.
  • 795 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Alethea Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.